-
for medical students, as well as for Tumor biology courses for biomedicine students and Pathology courses for opticians. Do you want to contribute by connecting the latest cancer proteome research to patient
-
multiomics analysis of ALS, focusing on integrating genomics, metagenomics, and proteomics data. Additionally, the candidate will participate in a research project focused on identifying pathways to lead the
-
. Excellent communication skills and fluent English. Additional merits: Experience in handling analyses of large data sets, e.g. RNA-seq, proteomic, metabolomics data, multiparameter flow cytometry data
-
immune cell populations to validate single cell RNA sequencing and proteomic results. Serological study on human cohort will be assessed ELISA and Luminex-based method to determine the antibody
-
systems. The Fossati lab investigates bacterial immune systems composition and mechanism by employing a combination of bulk NGS technologies and high-throughput interaction proteomics approaches (Fossati et
-
receiving immune checkpoint inhibitors and potential impact from radiotherapy. You will design and carry out proteomic profiling with front-line technologies, in an independent way, on EVs from sequentially
-
, including metabolomics, proteomics, and transcriptomics and use them to identify systems-level mechanisms in cancer to enhance treatment efficacy by uncovering new drug targets, biomarkers, and resistance
-
metabolism, signaling, and gene regulation and are constrained to align with physical interactions between biomolecules. We train the models on high-throughput datasets, including metabolomics, proteomics, and
-
on amyotrophic lateral sclerosis (ALS). We are particularly interested in understanding how different neurons modulate their epigenome, transcriptome, and proteome in response to disease-inducing mutations
-
to investigate the role of early life events in the development of early onset obstructive lung disease. Your mission The overall project involves molecular characterization at the mRNA, miRNA, proteome and